Merck notches 38th approval for Keytruda, seventh indication for gastrointestinal cancer
The FDA on Thursday approved Merck’s anti-PD-1 therapy to treat a type of gastrointestinal cancer in combination with chemotherapy, marking the drug’s 38th indication.
The approval is to treat locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma when used in combination with fluoropyrimidine- and platinum-containing chemotherapy. It marks the drug’s seventh indication for gastrointestinal cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.